http://purl.org/np/RA2lJMJnoFazPLIsZ8RXaWd2LfIlDNLBehSRq9xySI-0Q#Head
http://purl.org/np/RA2lJMJnoFazPLIsZ8RXaWd2LfIlDNLBehSRq9xySI-0Q
http://www.nanopub.org/nschema#hasAssertion
http://purl.org/np/RA2lJMJnoFazPLIsZ8RXaWd2LfIlDNLBehSRq9xySI-0Q#assertion
http://purl.org/np/RA2lJMJnoFazPLIsZ8RXaWd2LfIlDNLBehSRq9xySI-0Q
http://www.nanopub.org/nschema#hasProvenance
http://purl.org/np/RA2lJMJnoFazPLIsZ8RXaWd2LfIlDNLBehSRq9xySI-0Q#provenance
http://purl.org/np/RA2lJMJnoFazPLIsZ8RXaWd2LfIlDNLBehSRq9xySI-0Q
http://www.nanopub.org/nschema#hasPublicationInfo
http://purl.org/np/RA2lJMJnoFazPLIsZ8RXaWd2LfIlDNLBehSRq9xySI-0Q#pubinfo
http://purl.org/np/RA2lJMJnoFazPLIsZ8RXaWd2LfIlDNLBehSRq9xySI-0Q
http://www.w3.org/1999/02/22-rdf-syntax-ns#type
http://www.nanopub.org/nschema#Nanopublication
http://purl.org/np/RA2lJMJnoFazPLIsZ8RXaWd2LfIlDNLBehSRq9xySI-0Q#assertion
http://purl.obolibrary.org/obo/DOID_1558
https://w3id.org/biolink/vocab/category
https://w3id.org/biolink/vocab/Disease
http://purl.org/np/RA2lJMJnoFazPLIsZ8RXaWd2LfIlDNLBehSRq9xySI-0Q#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#object
http://purl.obolibrary.org/obo/DOID_1558
http://purl.org/np/RA2lJMJnoFazPLIsZ8RXaWd2LfIlDNLBehSRq9xySI-0Q#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#predicate
https://w3id.org/biolink/vocab/treats
http://purl.org/np/RA2lJMJnoFazPLIsZ8RXaWd2LfIlDNLBehSRq9xySI-0Q#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#subject
https://identifiers.org/drugbank:DB14213
http://purl.org/np/RA2lJMJnoFazPLIsZ8RXaWd2LfIlDNLBehSRq9xySI-0Q#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#type
http://www.w3.org/1999/02/22-rdf-syntax-ns#Statement
http://purl.org/np/RA2lJMJnoFazPLIsZ8RXaWd2LfIlDNLBehSRq9xySI-0Q#association
http://www.w3.org/2000/01/rdf-schema#label
"Perindopril erbumine tablets are contraindicated in patients known to be hypersensitive (including angioedema) to this product or to any other ACE inhibitor. Perindopril erbumine tablets are also contraindicated in patients with hereditary or idiopathic angioedema. [see Drug Interactions (7.8) ] [see Warnings and Precautions (5.1) Angioedema related to previous treatment with an ACE inhibitor, or a history of hereditary or idiopathic angioedema. ( 4 5.1 Do not co-administer aliskiren with perindopril erbumine tablets in patients with diabetes ( 4 7.8 Do not take a neprilysin inhibitor with perindopril erbumine tablets ( 4 Do not administer perindopril erbumine tablets within 36 hours of switching to or from sacubitril/valsartan ( 4"
http://purl.org/np/RA2lJMJnoFazPLIsZ8RXaWd2LfIlDNLBehSRq9xySI-0Q#association
https://w3id.org/biolink/vocab/provided_by
https://w3id.org/um/NeuroDKG
http://purl.org/np/RA2lJMJnoFazPLIsZ8RXaWd2LfIlDNLBehSRq9xySI-0Q#association
https://w3id.org/biolink/vocab/relation
https://schema.org/MedicalContraindication
https://identifiers.org/drugbank:DB14213
https://w3id.org/biolink/vocab/category
https://w3id.org/biolink/vocab/Drug
http://purl.org/np/RA2lJMJnoFazPLIsZ8RXaWd2LfIlDNLBehSRq9xySI-0Q#provenance
http://purl.org/np/RA2lJMJnoFazPLIsZ8RXaWd2LfIlDNLBehSRq9xySI-0Q#assertion
http://www.w3.org/ns/prov#wasAttributedTo
https://orcid.org/0000-0002-1468-3557
http://purl.org/np/RA2lJMJnoFazPLIsZ8RXaWd2LfIlDNLBehSRq9xySI-0Q#pubinfo
http://purl.org/np/RA2lJMJnoFazPLIsZ8RXaWd2LfIlDNLBehSRq9xySI-0Q#sig
http://purl.org/nanopub/x/hasAlgorithm
RSA
http://purl.org/np/RA2lJMJnoFazPLIsZ8RXaWd2LfIlDNLBehSRq9xySI-0Q#sig
http://purl.org/nanopub/x/hasPublicKey
MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCODwZkXojpEKwk7Ldj2oPPfCstvqrcpgCaTLo235K7ht9C7E1GCkLvUuL2b4VWXJTcZx/hxgDauR8hUeYq/lS6tfTL9yFZsnfl+PWYDyz7vv6N+wJVx2LL8bO6ntCjcOzvW2t2WUeF12Sb6b3I6uOYP0N8iQKts1WasY/yEYKAHQIDAQAB
http://purl.org/np/RA2lJMJnoFazPLIsZ8RXaWd2LfIlDNLBehSRq9xySI-0Q#sig
http://purl.org/nanopub/x/hasSignature
SQlyhJ8miHaMfcgbRB6fYUABwZ0xjJ0pgQYCZacIZlZeIZIPzRX6dkjktoxJrVPuBCEPuHoxg8Qo4wntZ/lS8TgPnmJ76Z/jFCRwWM+oRL2f49tE4SjZ59xk4cT45kfsnI2pjw50r0TkmMebZJ/kjWSJlSTGUy4gnGr59YDLDH0=
http://purl.org/np/RA2lJMJnoFazPLIsZ8RXaWd2LfIlDNLBehSRq9xySI-0Q#sig
http://purl.org/nanopub/x/hasSignatureTarget
http://purl.org/np/RA2lJMJnoFazPLIsZ8RXaWd2LfIlDNLBehSRq9xySI-0Q
http://purl.org/np/RA2lJMJnoFazPLIsZ8RXaWd2LfIlDNLBehSRq9xySI-0Q
http://purl.org/dc/terms/created
2021-08-25T13:42:34.473+02:00
http://purl.org/np/RA2lJMJnoFazPLIsZ8RXaWd2LfIlDNLBehSRq9xySI-0Q
http://purl.org/dc/terms/creator
https://orcid.org/0000-0002-1468-3557
http://purl.org/np/RA2lJMJnoFazPLIsZ8RXaWd2LfIlDNLBehSRq9xySI-0Q
https://w3id.org/np/o/ntemplate/wasCreatedFromProvenanceTemplate
http://purl.org/np/RANwQa4ICWS5SOjw7gp99nBpXBasapwtZF1fIM3H2gYTM
http://purl.org/np/RA2lJMJnoFazPLIsZ8RXaWd2LfIlDNLBehSRq9xySI-0Q
https://w3id.org/np/o/ntemplate/wasCreatedFromPubinfoTemplate
http://purl.org/np/RAA2MfqdBCzmz9yVWjKLXNbyfBNcwsMmOqcNUxkk1maIM
http://purl.org/np/RA2lJMJnoFazPLIsZ8RXaWd2LfIlDNLBehSRq9xySI-0Q
https://w3id.org/np/o/ntemplate/wasCreatedFromTemplate
http://purl.org/np/RAhNHZw6Urw_Mccs4qy6Ws3C9CRuaHpQx8AwuApbWkqnY